Skip to main content
. 2015 Jul 29;56(5):1251–1257. doi: 10.3349/ymj.2015.56.5.1251

Supplementary Table 2. In Vitro Characteristics of Selected Chemicals with Docking Score Order 51-100.

Lab No.* Docking score ChemBridge ID MW Relative inhibition Dil-LDL uptake LDLR§ PCSK9§
CBC_51 26.99 7127155 468.5 -2.6% 0.95 0.74 0.85
CBC_52 26.99 7010655 295.4 15.4% 1.80 1.41 0.60
CBC_53 26.98 6707210 409.6 28.4% 1.74 1.16 0.75
CBC_54 26.98 7980928 391.9 2.6% 1.74 1.09 0.87
CBC_55 26.97 7059604 448.4 -5.3% 1.03 0.51 0.67
CBC_56 26.95 9006787 370.4 26.1% 1.02 1.40 0.50
CBC_57 26.94 6991769 318.5 12.5% 2.18 1.10 0.46
CBC_58 26.89 7116267 469.6 -27.9% 1.49 1.43 0.23
CBC_59 26.86 6587027 339.8 -5.8% 1.18 0.53 0.00
CBC_60 26.85 5537034 332.4 4.6% 0.94 0.61 0.16
CBC_61 26.84 6578162 459.6 14.9% 1.03 1.26 0.74
CBC_62 26.81 9011745 356.4 4.7% 1.02 0.70 0.15
CBC_63 26.81 7913488 402.5 -11.1% 0.90 0.45 0.57
CBC_64 26.79 6447900 400.5 -0.6% 2.04 1.27 0.72
CBC_65 26.79 7261073 353.5 -1.8% 1.17 0.98 0.26
CBC_66 26.78 7943026 493.4 10.2% 1.93 0.83 0.60
CBC_67 26.75 5252938 378.4 -10.6% 1.08 0.44 0.79
CBC_68 26.74 5426872 389.5 10.0% 0.52 0.65 0.41
CBC_69 26.74 7970741 345.5 5.8% 1.22 1.18 0.88
CBC_70 26.73 9025813 348.4 9.8% 2.06 1.23 0.59
CBC_71 26.69 7547620 361.4 -8.5% 1.01 0.68 0.41
CBC_72 26.69 5723280 330.4 25.8% 1.21 1.06 1.28
CBC_73 26.68 5425499 345.5 18.9% 1.93 1.76 1.26
CBC_74 26.67 7968546 341.5 19.6% 1.94 1.48 1.49
CBC_75 26.67 5665101 459.5 -1.5% 1.23 0.52 0.75
CBC_76 26.66 7873145 381.5 7.0% 1.10 0.70 0.33
CBC_77 26.66 9036091 337.4 16.0% 1.18 0.82 1.06
CBC_78 26.64 7543524 368.4 -2.7% 1.44 0.77 0.23
CBC_79 26.62 5427177 398.5 52.3% 1.76 0.98 0.62
CBC_80 26.62 7924529 299.4 6.9% 1.49 1.36 1.18
CBC_81 26.62 7232922 431.5 -10.0% 1.35 1.20 0.15
CBC_82 26.61 6759201 397.6 12.1% 1.32 1.65 1.45
CBC_83 26.61 9014232 327.8 22.5% 2.08 0.97 0.61
CBC_84 26.59 7997500 377.5 11.9% 1.34 1.62 1.80
CBC_85 26.59 7924880 329.5 18.6% 1.44 1.31 1.22
CBC_86 26.58 9038237 348.4 8.4% 1.54 1.22 0.89
CBC_87 26.55 7966644 385.5 11.2% 1.80 1.60 1.37
CBC_88 26.48 7595292 373.9 3.3% 1.09 0.65 0.08
CBC_89 26.48 7968661 475.5 3.2% 1.26 1.21 0.39
CBC_90 26.47 7839314 389.4 6.2% 0.76 1.47 0.95
CBC_91 26.44 7889540 366.4 2.5% 1.12 2.08 0.76
CBC_92 26.43 9030034 422.4 1.1% 1.46 1.44 0.59
CBC_93 26.41 6484579 375.5 2.3% 1.18 1.26 0.78
CBC_94 26.39 7280568 366.5 -5.6% 1.11 1.03 0.91
CBC_95 26.35 7934110 416.5 -12.5% 0.91 1.19 0.64
CBC_96 26.34 6659178 403.4 -11.3% 1.01 0.59 0.86
CBC_97 26.33 9019728 371.5 -0.2% 1.44 0.97 1.01
CBC_98 26.32 7633305 397.4 6.0% 1.05 0.97 0.05
CBC_99 26.31 7791626 434.6 11.5% 0.91 0.74 0.84
CBC_100 26.24 7933432 444.5 -3.0% 0.85 0.62 0.68

MW, molecular weight; LDL, low density lipoprotein; LDLR, LDL receptor; PCSK9, proprotein convertase subtilisin/kexin type 9.

*Lab No. is arbitrarily denoted according to the order of the ChemBridge ID number, Relative inhibition represents the difference in percentile between the intensity of PCSK9-LDLR in the presence of the chemical and that in the presence of the vehicle (DMSO), which was set as 100%, Dil-LDL uptake denotes the factor of the mean fluorescence intensity in HepG2 cells treated with each chemical compared to that in cells treated with the vehicle, §The amount of LDLR or PCSK9 denotes the factor of the signal for LDLR or PCSK9, respectively, from immunoblot data analyzed by ImageJ.